Janux Therapeutics Inc.

04/29/2024 | Press release | Distributed by Public on 04/29/2024 14:21

Additional Proxy Soliciting Materials - Form DEFA14A

DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Janux Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Janux P.O. BOX 8016, CARY, NC 27512-9903 Janux Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 26, 2024 For Stockholders of record as of April 29, 2024 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/JANX To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/JANX Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 14, 2024. To order paper materials, use one of the following methods. INTERNET www.investorelections.com/JANX TELEPHONE (866) 648-8133 * E-MAIL [email protected] " If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above. Janux Therapeutics, Inc. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Meeting Type: Annual Meeting of Stockholders Date: Wednesday, June 26, 2024 Time: 1 :30 PM, Pacific Time Place: Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/JANX for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/JANX SEE REVERSEFORFULLAGENDA

Janux Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 ROPOSAL 1. To elect the three nominees for Class Ill director named in the proxy statement to serve for three-year terms until the 2027 Annual Meeting of Stockholders. 1 .01 Vickie Capps 1 .02 Jay Lichter 1 .03 Jake Simson 2. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. 3. To conduct any other business properly brought before the meeting.